

AMENDMENTS TO THE SPECIFICATION

Please delete the following paragraph starting at page one, line 20, of the specification:

--As is well known to those skilled in the art, the known and potential uses of compounds having activity at the somatostatin receptor are varied and multitudinous. Thus, the administration of an imidazolyl derivative of this invention which binds selectively to somatostatin receptor subtypes can treat medical disorders which are mediated by somatostatin receptor subtypes. For example, for treating acromegaly, *see, e.g.*, Robbins, R.J., J. Clin. Endocr. Metab., 82:15-17 (1997); for treating restenosis, *see, e.g.*, Grant, M.B., et al., Circulation, 89:1511-1517 (1994); for treating Crohn's disease, *see, e.g.*, Fedorak, R.N., et al., Can. J. Gastroenterology, 3, No. 2, 53-57 (1989); for treating systemic sclerosis, *see, e.g.*, Soudah, H., et al., Gastroenterology, 98, No. 5, Part 2, Suppl., A129 (1990); for treating external and internal pancreatic pseudocysts and ascites, *see, e.g.*, Hartley, J.E., et al., J. Roy. Soc. Med., 85, pp. 107-108 (1992); for treating VIPoma, *see, e.g.*, Koberstein, B., et al., Z. Gastroenterology, 28, 295-301 (1990); for treating nesidoblastosis and hyperinsulinism, *see, e.g.*, Laron, Z., Israel J. Med. Sci., 26, No. 1, 1-2 (1990); for treating gastrinoma, *see, e.g.*, Bauer, W., Europ. J. Pharmacol., 183, 55 (1990); for treating Zollinger-Ellison Syndrome, *see, e.g.*, Mozell, E., et al., Surg. Gynec. Obstet., 170, 476-484 (1990); for treating AIDS related diarrhea, *see, e.g.*, Cello, J.P., et al., Gastroenterology, 98, No. 5, Part 2, Suppl., A163 (1990); for treating chemotherapy related diarrhea, *see, e.g.*, Petrelli, N., et al., Proc. Amer. Soc. Clin. Oncol., Vol. 10, P 138, Abstr. No. 417 (1991); for treating scleroderma, *see, e.g.*, Soudah, H., et al., Clin. Res., Vol. 39, p. 303A (1991); for treating Irritable Bowel Syndrome, *see, e.g.*, O'Donnell, L.J.D., et al., Aliment. Pharmacol. Therap., Vol. 4., 177-181 (1990); for treating pancreatitis, *see, e.g.*, Tulassay, Z., et al., Gastroenterology, 98, No. 5, Part 2, Suppl., A238 (1990); for treating small bowel obstruction, *see, e.g.*, Nott, D.M., et al., Brit. J. Surg., Vol. 77, p. A691 (1990); for treating gastroesophageal reflux, *see, e.g.*, Branch, M.S., et al., Gastroenterology, Vol. 100, No. 5, Part 2 Suppl., p. A425 (1991); for treating duodenogastric reflux, *see, e.g.*, Hasler, W., et al., Gastroenterology, Vol. 100, No. 5, Part 2, Suppl., p. A448 (1991); for treating Cushing's Syndrome, *see, e.g.*, Clark, R.V., et al., Clin. Res. 38, p. 943A (1990); for treating

gonadotropinoma, *see, e.g.*, Ambrosi B., et al., Acta Endocr. (Copenh.) 122, 569-576 (1990); for treating hyperparathyroidism, *see, e.g.*, Miller, D., et al., Canad. Med. Ass. J., Vol. 145, pp. 227-228 (1991); for treating Graves' Disease, *see, e.g.*, Chang, T.C., et al., Brit. Med. J., 304, p. 158 (1992); for treating diabetic neuropathy, *see, e.g.*, Chan, A.W., et al., Horm. Res., 36:86-87 (1991); for treating Paget's disease, *see, e.g.*, Palmieri, G.M.A., et al., J. of Bone and Mineral Research, 7, (Suppl. 1), p. S240 (Abs. 591) (1992); for treating polycystic ovary disease, *see, e.g.*, Prelevic, G.M., et al., Metabolism Clinical and Experimental, 41, Suppl. 2, pp 76-79 (1992); for treating cancer, *see, e.g.*, Weckbecker, G., et al., Pharmac. Ther., 60:245-264 (1993); for treating cancer cachexia, *see, e.g.*, Bartlett, D.L., et al., Surg. Forum., 42, pp. 14-16 (1991); for treating hypotension, *see, e.g.*, Hoeldtke, R.D., et al., Arch. Phys. Med. Rehabil., 69, 895-898 (1988); for treating postprandial hypotension, *see, e.g.*, Hoeldtke, R.D., et al., Am. J. Med., 81:83-87 (1986); for treating panic attacks, *see, e.g.*, Abelson, J.L., et al., Clin. Psychopharmacol., 10, 128-132 (1990); for treating GH secreting adenomas or TSH secreting adenomas, *see, e.g.*, Malarkey, W.B., et al., Neuroendocrinology, 49:267-274 (1989); for treating diabetes mellitus, *see, e.g.*, Dimitriadis, G., et al., Metabolism, 32:987-992 (1983); for treating hyperlipidemia, *see, e.g.*, U.S. Patent No. 7,026,289; for treating insulin insensitivity, *see, e.g.*, Orskov, L., et al., Metabolism, 45:211-217 (1996); for treating Syndrome X, *see, e.g.*, U.S. Patent Application No. US-2004-0072734-A1; for treating proliferative retinopathy, *see, e.g.*, McCombe, M., et al., Eye, 5:569-575 (1991); for treating dawn phenomenon, *see, e.g.*, Campbell, P.J., et al., Metabolism, 37:34-37 (1988); for treating Nephropathy, *see, e.g.*, Flyvbjerg, A., et al., Kidney Int., 41:805-812 (1992); for treating peptic ulcers, *see, e.g.*, Kayasseh L, Lancet, 1:844-846 (1980); for treating enterocutaneous fistula, *see, e.g.*, Nubiola, P., et al., Ann. Surg., 210:56-58 (1989); for treating pancreaticocutaneous fistula, *see, e.g.*, Anand, B.S., et al., Am. J. Gastroenterol., 89:267-270 (1994); for treating Dumping syndrome, *see, e.g.*, Hopman, W.P., et al., Ann. Surg., 207:155-159 (1988); for treating watery diarrhea syndrome, *see, e.g.*, Eriksson, B., et al., Scand. J. Gastroenterol., 23:508-512 (1988); for treating acute or chronic pancreatitis, *see, e.g.*, Buchler, M.W., et al., Gut, 35:S15-S19 (1994); for treating gastrointestinal hormone secreting tumors, *see, e.g.*, Souquet, J.C., et al., Cancer, 59:1654-1660 (1987); for treating angiogenesis, *see, e.g.*, Danesi, R., et al., Clin. Cancer Res., 3:265-72 (1997); for treating inflammatory disorders, *see, e.g.*, Mantyh, P.W., et al., Peptides, 10:627-645 (1989); for treating chronic allograft rejection,

Inventor : Thurieu *et al.*
Serial No. : 10/771,725
Filed : February 4, 2004
Page : 4

see, e.g., Hayry, P., et al., FASEB J. 7:1055-1060 (1993); for treating angioplasty, *see, e.g.*, Yumi, K., et al., Lab. Invest., 76:329-338 (1997); for treating gastrointestinal bleeding, *see, e.g.*, Rossini, F.P., et al., Am. J. Gastroenterol., 88:1424-1427 (1993); and for inhibiting the proliferation of helicobacter pylori, *see, e.g.*, Ladas, S.D., et al., Hepatogastroenterology, 45:761-4 (1998).--